Reference | Year | Country | Study design | Enrollment period | Patients | Location | Sample | Cut-off | Sen | Spe | Standard | Received antibiotics | Excluded inflammatory disease |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
[23] | 2010 | Argentina | Prospective study | February 2007 and July 2008 | 69 | Hip | IL-6 | 10 pg/ml | 36% | 94% | H, M | N | Y |
CRP | 10 mg/l | 72% | 91% | ||||||||||
IL-6 + CRP (Serial tests) | 57% | 100% | |||||||||||
[24] | 2007 | Germany | Prospective study | July 2003 and March 2004 | 78 | Hip, knee | IL-6 | > 12 pg/ml | 95% | 87% | H, M | NA | N |
CRP | > 3.2 mg/l | 95% | 96% | ||||||||||
IL-6 + CRP (Parallel test) | 100% | 86% | |||||||||||
[8] | 2017 | Turkey | Prospective study | April 2010 and December 2012 | 85 | Knee | IL-6 | 6.6 pg/ml | 95% | 96% | MSIS | N | Y |
CRP | 8.83 mg/l | 95% | 90% | ||||||||||
IL-6 + CRP (Parallel test) | 99% | 98% | |||||||||||
[4] | 2013 | Egypt | Prospective study | NA | 40 | Hip, knee | IL-6 | > 10.4 pg/ml | 100% | 90.90% | H, M, P | N | Y |
CRP | > 18 mg/l | 100% | 86.20% | ||||||||||
IL-6 + CRP (Serial tests) | 100% | 99% | |||||||||||
[25] | 2019 | USA | Prospective study | January 2017 to December 2019 | 52 | Knee | IL-6 | > 9.14 pg/ml | 81.30% | 63% | MSIS | NA | Y |
CRP | > 17 mg/l | 66.70% | 66.70% | ||||||||||
IL-6 + CRP (Serial tests) | 33.30% | 85.0% | |||||||||||
IL-6 + CRP (Parallel test) | 93.8% | 45.8% | |||||||||||
[10] | 2013 | Austria | Prospective study | March 2008 and June 2010 | 84 | Hip, knee | IL-6 | 4.7 pg/ml | 81% | 68% | MSIS | Y | Y |
CRP | 17.05 mg/l | 84% | 79% | ||||||||||
IL-6 + CRP (Parallel test) | 84% | 68% | |||||||||||
[9] | 2015 | Germany | Prospective study | NA | 77 | Hip, knee | IL-6 | > 5.12 pg/ml | 80% | 87.70% | MSIS | N | Y |
CRP | ≥ 3 mg/l | 80% | 64% | ||||||||||
IL-6 + CRP (Serial tests) | 75% | 98.20% | |||||||||||
[26] | 2017 | China | Prospective study | August 2013 and August 2016 | 160 | Hip, knee | IL-6 | 6.9 pg/ml | 96.60% | 78% | MSIS | NA | Y |
CRP | 8.54 mg/l | 79.70% | 83.80% | ||||||||||
IL-6 + CRP (Serial tests) | 76.30% | 93.10% | |||||||||||
IL-6 + CRP (Parallel test) | 100% | 69.3% |